A Study of AZD0120 in Autoimmune Diseases

Summary

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Timeline

Start

2026-01-09

Primary completion

2028-02-22

Completion

2028-02-22

Drugs

Indications